Dark Forest Capital Management LP Sells 11,536 Shares of Arcellx, Inc. (NASDAQ:ACLX)

Dark Forest Capital Management LP decreased its holdings in shares of Arcellx, Inc. (NASDAQ:ACLX) by 41.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 16,067 shares of the company’s stock after selling 11,536 shares during the quarter. Dark Forest Capital Management LP’s holdings in Arcellx were worth $1,232,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Hsbc Holdings PLC increased its stake in Arcellx by 114.7% in the fourth quarter. Hsbc Holdings PLC now owns 6,383 shares of the company’s stock worth $496,000 after purchasing an additional 3,410 shares during the period. Tower Research Capital LLC TRC increased its stake in Arcellx by 1,081.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,984 shares of the company’s stock worth $612,000 after buying an additional 7,308 shares during the period. MetLife Investment Management LLC lifted its holdings in Arcellx by 4.3% during the 4th quarter. MetLife Investment Management LLC now owns 26,058 shares of the company’s stock valued at $1,998,000 after buying an additional 1,077 shares in the last quarter. Capital World Investors bought a new position in Arcellx in the 4th quarter worth about $19,393,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Arcellx by 156.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 305,088 shares of the company’s stock worth $23,400,000 after acquiring an additional 186,013 shares during the period. 96.03% of the stock is currently owned by hedge funds and other institutional investors.

Arcellx Stock Performance

Shares of NASDAQ ACLX opened at $63.63 on Thursday. The stock has a 50 day moving average price of $64.83 and a 200 day moving average price of $75.04. The firm has a market capitalization of $3.50 billion, a price-to-earnings ratio of -89.62 and a beta of 0.33. Arcellx, Inc. has a 52-week low of $47.88 and a 52-week high of $107.37.

Arcellx (NASDAQ:ACLX) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.24). Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. The firm had revenue of $15.27 million for the quarter, compared to the consensus estimate of $27.42 million. Analysts forecast that Arcellx, Inc. will post -1.58 earnings per share for the current year.

Insider Buying and Selling at Arcellx

In related news, insider Christopher Heery sold 10,155 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $63.79, for a total transaction of $647,787.45. Following the sale, the insider now owns 37,486 shares of the company’s stock, valued at $2,391,231.94. This trade represents a 21.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kavita Patel sold 1,500 shares of the business’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $71.64, for a total transaction of $107,460.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 54,455 shares of company stock valued at $3,408,458. Company insiders own 6.24% of the company’s stock.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).